The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to evaluate efficacy and safety of two different doses of
NEFECON in the treatment of patients with primary IgA nephropathy (IgAN) at risk of
developing end-stage renal disease, under rigorous blood pressure control with an
angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin II receptor I blocker
(ARB).